# CTS Corp: financial statements, quarterly

CTS · NYSE · CIK 26058 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/cts.md) · [Financials](/companies/cts/financials.md) · [Filings](/companies/cts/filings.md) · [Insiders](/companies/cts/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/cts/financials.md?period=annual).

## Income statement

| Line item | Unit | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [125 d](/filings/0001193125-26-067039.md) | [126](/filings/0000950170-25-060885.md) | [130](/filings/0000950170-25-098225.md) | [132](/filings/0001193125-25-253188.md) | [126 d](/filings/0001193125-26-067039.md) | [126](/filings/0001193125-26-190431.md) | [135](/filings/0001193125-26-320492.md) | [143](/filings/0001193125-26-433661.md) | [137 d](/filings/0001193125-26-067039.md) | [139](/filings/0001193125-26-190431.md) | [145](/filings/0001193125-26-320492.md) | [150](/filings/0001193125-26-433661.md) |
| Cost of revenue | $m | [82.6 d](/filings/0001193125-26-067039.md) | [80.7](/filings/0000950170-25-060885.md) | [83.8](/filings/0000950170-25-098225.md) | [83.2](/filings/0001193125-25-253188.md) | [79.6 d](/filings/0001193125-26-067039.md) | [79.2](/filings/0001193125-26-190431.md) | [82.9](/filings/0001193125-26-320492.md) | [87.6](/filings/0001193125-26-433661.md) | [83.6 d](/filings/0001193125-26-067039.md) | [84.2](/filings/0001193125-26-190431.md) | [84.7](/filings/0001193125-26-320492.md) | [86.4](/filings/0001193125-26-433661.md) |
| Gross profit | $m | [42.1 d](/filings/0001193125-26-067039.md) | [45.1](/filings/0000950170-25-060885.md) | [46.4](/filings/0000950170-25-098225.md) | [49.2](/filings/0001193125-25-253188.md) | [46.9 d](/filings/0001193125-26-067039.md) | [46.5](/filings/0001193125-26-190431.md) | [52.4](/filings/0001193125-26-320492.md) | [55.3](/filings/0001193125-26-433661.md) | [53.7 d](/filings/0001193125-26-067039.md) | [55.0](/filings/0001193125-26-190431.md) | [60.0](/filings/0001193125-26-320492.md) | [63.2](/filings/0001193125-26-433661.md) |
| Research and development | $m | [5.3 d](/filings/0001193125-26-067039.md) | [6.6](/filings/0000950170-25-060885.md) | [6.1](/filings/0000950170-25-098225.md) | [5.0](/filings/0001193125-25-253188.md) | [5.7 d](/filings/0001193125-26-067039.md) | [6.2](/filings/0001193125-26-190431.md) | [6.3](/filings/0001193125-26-320492.md) | [6.9](/filings/0001193125-26-433661.md) | [5.9 d](/filings/0001193125-26-067039.md) | [6.6](/filings/0001193125-26-190431.md) | [4.8](/filings/0001193125-26-320492.md) | [6.3](/filings/0001193125-26-433661.md) |
| Selling, general and administrative | $m | [19.5 d](/filings/0001193125-26-067039.md) | [22.3](/filings/0000950170-25-060885.md) | [21.3](/filings/0000950170-25-098225.md) | [22.5](/filings/0001193125-25-253188.md) | [22.2 d](/filings/0001193125-26-067039.md) | [23.6](/filings/0001193125-26-190431.md) | [23.1](/filings/0001193125-26-320492.md) | [27.2](/filings/0001193125-26-433661.md) | [24.8 d](/filings/0001193125-26-067039.md) | [26.0](/filings/0001193125-26-190431.md) | [28.4](/filings/0001193125-26-320492.md) | [30.8](/filings/0001193125-26-433661.md) |
| Operating income | $m | [16.3 d](/filings/0001193125-26-067039.md) | [14.5](/filings/0000950170-25-060885.md) | [17.8](/filings/0000950170-25-098225.md) | [20.9](/filings/0001193125-25-253188.md) | [18.0 d](/filings/0001193125-26-067039.md) | [16.3](/filings/0001193125-26-190431.md) | [22.7](/filings/0001193125-26-320492.md) | [20.9](/filings/0001193125-26-433661.md) | [22.7 d](/filings/0001193125-26-067039.md) | [22.0](/filings/0001193125-26-190431.md) | [26.8](/filings/0001193125-26-320492.md) | [25.5](/filings/0001193125-26-433661.md) |
| Interest expense | $m | [0.8 d](/filings/0000950170-24-019292.md) | [0.8](/filings/0000950170-24-051203.md) | [0.8](/filings/0000950170-24-087814.md) | [1.3](/filings/0001193125-25-253188.md) | [1.3 d](/filings/0001193125-26-067039.md) | [1.2](/filings/0001193125-26-190431.md) | [1.1](/filings/0001193125-26-320492.md) | [1.1](/filings/0001193125-26-433661.md) | [0.9 d](/filings/0001193125-26-067039.md) | [0.7](/filings/0001193125-26-190431.md) | [0.7](/filings/0001193125-26-320492.md) | [0.6](/filings/0001193125-26-433661.md) |
| Income tax | $m | [2.3 d](/filings/0001193125-26-067039.md) | [2.5](/filings/0000950170-25-060885.md) | [3.1](/filings/0000950170-25-098225.md) | [3.8](/filings/0001193125-25-253188.md) | [3.7 d](/filings/0001193125-26-067039.md) | [2.8](/filings/0001193125-26-190431.md) | [4.5](/filings/0001193125-26-320492.md) | [6.0](/filings/0001193125-26-433661.md) | [5.2 d](/filings/0001193125-26-067039.md) | [4.5](/filings/0001193125-26-190431.md) | [7.1](/filings/0001193125-26-320492.md) | [20.5](/filings/0001193125-26-433661.md) |
| Net income | $m | [15.3 d](/filings/0001193125-26-067039.md) | [11.1](/filings/0001193125-25-253188.md) | [14.7](/filings/0001193125-25-253188.md) | [18.1](/filings/0001193125-25-253188.md) | [11.6 d](/filings/0001193125-26-067039.md) | [13.4](/filings/0001193125-26-433661.md) | [18.5](/filings/0001193125-26-433661.md) | [13.7](/filings/0001193125-26-433661.md) | [19.7 d](/filings/0001193125-26-067039.md) | [17.2](/filings/0001193125-26-433661.md) | [19.2](/filings/0001193125-26-433661.md) | [17.8](/filings/0001193125-26-433661.md) |
| Diluted EPS | $ per share | not reported | [0.36](/filings/0000950170-25-060885.md) | [0.48](/filings/0000950170-25-098225.md) | [0.59](/filings/0001193125-25-253188.md) | not reported | [0.44](/filings/0001193125-26-190431.md) | [0.62](/filings/0001193125-26-320492.md) | [0.46](/filings/0001193125-26-433661.md) | not reported | [0.59](/filings/0001193125-26-190431.md) | [0.66](/filings/0001193125-26-320492.md) | [0.61](/filings/0001193125-26-433661.md) |
| Basic EPS | $ per share | not reported | [0.36](/filings/0000950170-25-060885.md) | [0.48](/filings/0000950170-25-098225.md) | [0.60](/filings/0001193125-25-253188.md) | not reported | [0.45](/filings/0001193125-26-190431.md) | [0.62](/filings/0001193125-26-320492.md) | [0.47](/filings/0001193125-26-433661.md) | not reported | [0.60](/filings/0001193125-26-190431.md) | [0.67](/filings/0001193125-26-320492.md) | [0.62](/filings/0001193125-26-433661.md) |

- Revenue: us-gaap:Revenues
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [164](/filings/0000950170-25-027956.md) | [162](/filings/0000950170-24-051203.md) | [161](/filings/0000950170-24-087814.md) | [94.9](/filings/0000950170-24-118192.md) | [94.3](/filings/0001193125-26-067039.md) | [90.3](/filings/0000950170-25-060885.md) | [99.4](/filings/0000950170-25-098225.md) | [110](/filings/0001193125-25-253188.md) | [82.3](/filings/0001193125-26-433661.md) | [90.9](/filings/0001193125-26-190431.md) | [108](/filings/0001193125-26-320492.md) | [144](/filings/0001193125-26-433661.md) |
| Current assets | $m | [319](/filings/0000950170-25-027956.md) | [318](/filings/0000950170-24-051203.md) | [315](/filings/0000950170-24-087814.md) | [254](/filings/0001193125-25-253188.md) | [242](/filings/0001193125-26-067039.md) | [244](/filings/0000950170-25-060885.md) | [262](/filings/0000950170-25-098225.md) | [276](/filings/0001193125-25-253188.md) | [253](/filings/0001193125-26-433661.md) | [266](/filings/0001193125-26-190431.md) | [286](/filings/0001193125-26-320492.md) | [329](/filings/0001193125-26-433661.md) |
| Total assets | $m | [741](/filings/0000950170-25-027956.md) | [733](/filings/0000950170-24-051203.md) | [726](/filings/0000950170-24-087814.md) | [790](/filings/0001193125-25-253188.md) | [765](/filings/0001193125-26-067039.md) | [766](/filings/0000950170-25-060885.md) | [785](/filings/0000950170-25-098225.md) | [790](/filings/0001193125-25-253188.md) | [764](/filings/0001193125-26-433661.md) | [777](/filings/0001193125-26-190431.md) | [792](/filings/0001193125-26-320492.md) | [822](/filings/0001193125-26-433661.md) |
| Current liabilities | $m | [97.0](/filings/0000950170-25-027956.md) | [95.9](/filings/0000950170-24-051203.md) | [92.4](/filings/0000950170-24-087814.md) | [105](/filings/0001193125-25-253188.md) | [98.5](/filings/0001193125-26-067039.md) | [92.4](/filings/0000950170-25-060885.md) | [100](/filings/0000950170-25-098225.md) | [105](/filings/0001193125-25-253188.md) | [110](/filings/0001193125-26-433661.md) | [105](/filings/0001193125-26-190431.md) | [110](/filings/0001193125-26-320492.md) | [127](/filings/0001193125-26-433661.md) |
| Total liabilities | $m | [214](/filings/0000950170-25-027956.md) | [212](/filings/0000950170-24-051203.md) | [203](/filings/0000950170-24-087814.md) | [259](/filings/0001193125-25-253188.md) | [237](/filings/0001193125-26-067039.md) | [227](/filings/0000950170-25-060885.md) | [235](/filings/0000950170-25-098225.md) | [243](/filings/0001193125-25-253188.md) | [213](/filings/0001193125-26-433661.md) | [220](/filings/0001193125-26-190431.md) | [219](/filings/0001193125-26-320492.md) | [235](/filings/0001193125-26-433661.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [527](/filings/0001193125-26-067039.md) | [521](/filings/0001193125-25-253188.md) | [523](/filings/0001193125-25-253188.md) | [530](/filings/0001193125-25-253188.md) | [528](/filings/0001193125-26-433661.md) | [538](/filings/0001193125-26-433661.md) | [550](/filings/0001193125-26-433661.md) | [548](/filings/0001193125-26-433661.md) | [552](/filings/0001193125-26-433661.md) | [557](/filings/0001193125-26-433661.md) | [573](/filings/0001193125-26-433661.md) | [587](/filings/0001193125-26-433661.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Current portion of debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [32.1 d](/filings/0001193125-26-067039.md) | [18.3](/filings/0000950170-25-060885.md) | [19.6 d](/filings/0000950170-25-098225.md) | [35.4 d](/filings/0001193125-25-253188.md) | [24.9 d](/filings/0001193125-26-067039.md) | [15.5](/filings/0001193125-26-190431.md) | [28.4 d](/filings/0001193125-26-320492.md) | [29.0 d](/filings/0001193125-26-433661.md) | [29.2 d](/filings/0001193125-26-067039.md) | [17.3](/filings/0001193125-26-190431.md) | [33.4 d](/filings/0001193125-26-320492.md) | [43.5 d](/filings/0001193125-26-433661.md) |
| Capital expenditure | $m | [3.5 d](/filings/0001193125-26-067039.md) | [4.0](/filings/0000950170-25-060885.md) | [4.6 d](/filings/0000950170-25-098225.md) | [3.9 d](/filings/0001193125-25-253188.md) | [6.1 d](/filings/0001193125-26-067039.md) | [4.5](/filings/0001193125-26-190431.md) | [3.3 d](/filings/0001193125-26-320492.md) | [4.8 d](/filings/0001193125-26-433661.md) | [3.2 d](/filings/0001193125-26-067039.md) | [5.0](/filings/0001193125-26-190431.md) | [4.6 d](/filings/0001193125-26-320492.md) | [2.4 d](/filings/0001193125-26-433661.md) |
| Dividends paid | $m | [1.2 d](/filings/0001193125-26-067039.md) | [1.2](/filings/0000950170-25-060885.md) | [1.2 d](/filings/0000950170-25-098225.md) | [1.2 d](/filings/0001193125-25-253188.md) | [1.2 d](/filings/0001193125-26-067039.md) | [1.2](/filings/0001193125-26-190431.md) | [1.2 d](/filings/0001193125-26-320492.md) | [1.2 d](/filings/0001193125-26-433661.md) | [1.2 d](/filings/0001193125-26-067039.md) | [1.2](/filings/0001193125-26-190431.md) | [1.1 d](/filings/0001193125-26-320492.md) | [1.1 d](/filings/0001193125-26-433661.md) |
| Share repurchases | $m | [15.0 d](/filings/0001193125-26-067039.md) | [12.0](/filings/0000950170-25-060885.md) | [10.9 d](/filings/0000950170-25-098225.md) | [11.9 d](/filings/0001193125-25-253188.md) | [7.8 d](/filings/0001193125-26-067039.md) | [6.5](/filings/0001193125-26-190431.md) | [16.5 d](/filings/0001193125-26-320492.md) | [16.6 d](/filings/0001193125-26-433661.md) | [16.6 d](/filings/0001193125-26-067039.md) | [8.6](/filings/0001193125-26-190431.md) | [3.4 d](/filings/0001193125-26-320492.md) | [3.3 d](/filings/0001193125-26-433661.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets
- Dividends paid: us-gaap:PaymentsOfDividendsCommonStock
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [31.9](/filings/0000950170-24-051203.md) | [31.7](/filings/0000950170-24-087814.md) | [31.5](/filings/0000950170-24-118192.md) | [31.0](/filings/0000950170-25-060885.md) | [30.7](/filings/0000950170-25-098225.md) | [30.5](/filings/0001193125-25-253188.md) | [30.3](/filings/0001193125-26-190431.md) | [30.0](/filings/0001193125-26-320492.md) | [29.6](/filings/0001193125-26-433661.md) | [29.0](/filings/0001193125-26-190431.md) | [28.9](/filings/0001193125-26-320492.md) | [28.9](/filings/0001193125-26-433661.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 28,497,611 at 2026-10-20, from the cover of the [10-Q filed 2026-10-27](/filings/0001193125-26-433661.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 27, 2026, 13:44 ET. No prices; not investment advice.